Acumen Pharmaceuticals Presents Studies Showing the Utility of a pTau217 Assay in Screening for a Phase 2 Alzheimer’s Disease Trial and Validates Sabirnetug Oligomer-Selectivity, at the Alzheimer’s Association International Conference (AAIC) 2025

NEWTON, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced results showing that implementing a blood-based pTau217 screening assay reduced Acumen’s overall clinical trial screening costs by approximately 40% in its Phase 2 ALTITUDE-AD study of sabirnetug in early Alzheimer’s disease in the U.S. and Canada. Additionally, a nonclinical study revealed sabirnetug achieved the highest selectivity for AβOs over Aβ monomers relative to recombinant lecanemab and aducanumab. The results are being presented at the Alzheimer's Association International Conference (AAIC), taking place July 27-31, 2025, in Toronto and online.

Read more at globenewswire.com